Clinical trial
Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell…
NCT00445341 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00445341 |
|---|---|
| Title | Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma |
| Official title | A Phase I/II Study of Flavopiridol in Relapsed or Refractory Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma (DLBCL) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | Flavopiridol |
| Enrollment | 28 |
| Start date | Nov 27, 2006 |
| Primary completion | Apr 30, 2012 |
| Completion | Oct 18, 2012 |
| First posted | Mar 9, 2007 |
| Last update posted | Jan 30, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: